<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755091</url>
  </required_header>
  <id_info>
    <org_study_id>UM1HL112856 2011-06400</org_study_id>
    <secondary_id>UM1HL112856</secondary_id>
    <nct_id>NCT01755091</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea</brief_title>
  <acronym>PACE</acronym>
  <official_title>Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hektoen Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept study to determine the safety and efficacy of dronabinol for the
      treatment of obstructive sleep apnea syndrome (OSA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Apnea/Hypopnea Index (AHI)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment). The ESS scale has a range of 0 to 24, with 0 representing the least degree of sleepiness and 24 the greatest degree of sleepiness. There are no subscales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment). The Maintenance of Wakefulness Test measures a person's ability to stay awake in a quiet, dark and nonstimulating room for a period of time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability by Treatment Satisfaction Questionnaire for Medications (TSQM) Overall Score.</measure>
    <time_frame>Week 6</time_frame>
    <description>The TSQM measures a person's satisfaction with treatment based on a 7-point scale ranging from &quot;Extremely Dissatisfied&quot; to &quot;Extremely Satisfied&quot; in response to the question, &quot;Taking all things into account, how satisfied or dissatisfied are you with this medication?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>AEs will be evaluated and tracked throughout subject participation (up to 8 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Desaturation Time (DT)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <arm_group_label>2.5 mg/day</arm_group_label>
    <arm_group_label>10 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Dronabinol)</intervention_name>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult 21 to 64 years of age;

          -  15≤AHI ≤ 50 on screening polysomnogram (PSG)

          -  ESS score ≥ 7

          -  Able to understand and complete informed consent and all study assessments and forms,
             presented in an English-speaking format;

          -  Women of child-bearing potential (WCBP) must have a negative urine pregnancy test. In
             addition sexually active WCBP must agree to use adequate contraceptive methods (oral,
             injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine
             devices; barrier contraceptive with spermicide; or vasectomized partner).

        Exclusion Criteria:

          -  Arterial oxygen saturation &lt; 75% for &gt; 5% of sleep period time on screening PSG;

          -  Occupation or life situation that may impart risk by study participation (e.g.
             commercial driver, pilot, police officer, fireman);

          -  Motor vehicle accident or &quot;near-miss&quot; related to sleepiness (self-report) within 2
             years of the first dose of study drug (Day 8);

          -  Body mass index &gt; 45 kg/m2

          -  Severe obstructive sleep apnea syndrome (OSAS) that, based on the clinical judgment of
             the Investigator, precludes delaying positive airway pressure treatment;

          -  History of shift work or rotating shifts within the month prior to the first dose of
             study drug (Day 8);

          -  Prior upper airway surgery for snoring or OSAS as an adult (≥ 18 years of age);

          -  Prior non-invasive treatment for OSAS within 6 months prior to the first dose of study
             drug (Day 8);

          -  Major surgery within 6 months prior to the first dose of study drug (Day 8);

          -  Bariatric surgery within 2 years prior to the first dose of study drug (Day 8). If
             post-bariatric surgery, weight must be stable ±5% (self-report) for at least 6 months
             prior to first dose of study drug (Day 8).

          -  Any form of medically managed weight loss program within 6 months prior to the first
             dose of study drug (Day 8);

          -  Significant defect in nasal patency due to anatomical abnormalities or uncontrolled or
             recurrent episodes of rhinitis;

          -  Any clinically significant unstable or progressive medical condition;

          -  Any primary sleep disorder other than OSAS as determined by history, physical
             examination, or Visit 2 PSG (after 7-day screening run-in period);

          -  Clinically significant or uncontrolled: chronic obstructive pulmonary disease (COPD),
             cardiovascular disease, gastrointestinal, respiratory, pancreatic, hepatic, renal,
             hematologic, endocrine [including insulin-dependent diabetes mellitus (IDDM)],
             neurological, urogenital, connective tissue, dermatological, thyroid, or other medical
             disorder;

          -  Any clinically significant psychiatric disorder;

          -  History of seizure disorder;

          -  Treatment with any prescription antidepressant medication within 1 month prior to the
             first dose of study drug (Day 8);

          -  Treatment with sedatives, hypnotics or other psychoactive drugs within 30 days prior
             to the first dose of study drug (Day 8);

          -  Any complete blood count (CBC) or liver function test (LFT) laboratory value outside
             the normal range which, in the clinical judgment of the Investigator renders a subject
             inappropriate for randomization to treatment;

          -  Pregnancy [as demonstrated by positive urine human chorionic gonadotropin (hCG) test]
             or lactation;

          -  Allergic to cannabinoids or sesame oil;

          -  History of substance abuse (including alcohol abuse or dependence) or laboratory
             evidence of drug abuse on the Visit 1 drug-screening panel;

          -  Use of dietary supplements which in the judgment of the Investigator may impact sleep
             or breathing behaviors;

          -  Average daily caffeine consumption &gt; 500 mg/day (~5 cups of coffee);

          -  Average weekly alcohol consumption &gt; 10 units;

          -  Unwillingness to abstain from caffeine and alcohol on all days when overnight or
             daytime testing will be performed;

          -  Participation in any other investigational protocol within the 30 days prior to the
             first dose of study drug (Day 8);

          -  Any condition which, in the opinion of the Investigator, places the patient at
             unacceptable risk if he or she were to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Carley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>November 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2017</results_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>David W. Carley</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from physician referrals at two academic medical centers as well as from the community based upon print and radio advertising between January 2013 and May 2016. The first participant was enrolled in February 2013 and the last participant was enrolled in April 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
        </group>
        <group group_id="P2">
          <title>2.5 mg/Day</title>
          <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
        </group>
        <group group_id="P3">
          <title>10 mg/Day</title>
          <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population includes all participants who were randomized to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
        </group>
        <group group_id="B2">
          <title>2.5 mg/Day</title>
          <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
        </group>
        <group group_id="B3">
          <title>10 mg/Day</title>
          <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.39" spread="6.33"/>
                    <measurement group_id="B2" value="33.19" spread="5.09"/>
                    <measurement group_id="B3" value="33.45" spread="4.85"/>
                    <measurement group_id="B4" value="33.35" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apnea/Hypopnea Index</title>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.72" spread="9.47"/>
                    <measurement group_id="B2" value="27.54" spread="12.57"/>
                    <measurement group_id="B3" value="26.04" spread="11.92"/>
                    <measurement group_id="B4" value="25.67" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minimum Arterial Oxygen Saturation</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.58" spread="9.62"/>
                    <measurement group_id="B2" value="79.82" spread="6.83"/>
                    <measurement group_id="B3" value="79.96" spread="6.93"/>
                    <measurement group_id="B4" value="79.79" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep Efficiency</title>
          <description>Sleep Efficiency is calculated as the total time spent asleep divided by the total amount of time spent in bed, multiplied by 100.</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.51" spread="12.50"/>
                    <measurement group_id="B2" value="80.52" spread="11.11"/>
                    <measurement group_id="B3" value="82.74" spread="12.22"/>
                    <measurement group_id="B4" value="79.58" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Apnea/Hypopnea Index (AHI)</title>
        <description>Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment)</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Analysis performed including all participants who completed the full 6-weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg/Day</title>
            <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
          </group>
          <group group_id="O3">
            <title>10 mg/Day</title>
            <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apnea/Hypopnea Index (AHI)</title>
          <description>Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment)</description>
          <population>Analysis performed including all participants who completed the full 6-weeks of treatment.</population>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.99" spread="13.16"/>
                    <measurement group_id="O2" value="-1.71" spread="11.74"/>
                    <measurement group_id="O3" value="-5.21" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Epworth Sleepiness Scale (ESS)</title>
        <description>Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment). The ESS scale has a range of 0 to 24, with 0 representing the least degree of sleepiness and 24 the greatest degree of sleepiness. There are no subscales.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Data are missing for 2 participants randomized to receive Placebo treatment; due to technical error in not completing this instrument.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg/Day</title>
            <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
          </group>
          <group group_id="O3">
            <title>10 mg/Day</title>
            <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Epworth Sleepiness Scale (ESS)</title>
          <description>Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment). The ESS scale has a range of 0 to 24, with 0 representing the least degree of sleepiness and 24 the greatest degree of sleepiness. There are no subscales.</description>
          <population>Data are missing for 2 participants randomized to receive Placebo treatment; due to technical error in not completing this instrument.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="3.29"/>
                    <measurement group_id="O2" value="-.26" spread="2.94"/>
                    <measurement group_id="O3" value="-4.00" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)</title>
        <description>Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment). The Maintenance of Wakefulness Test measures a person's ability to stay awake in a quiet, dark and nonstimulating room for a period of time.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg/Day</title>
            <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
          </group>
          <group group_id="O3">
            <title>10 mg/Day</title>
            <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)</title>
          <description>Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment). The Maintenance of Wakefulness Test measures a person's ability to stay awake in a quiet, dark and nonstimulating room for a period of time.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="13.09"/>
                    <measurement group_id="O2" value="-3.70" spread="9.73"/>
                    <measurement group_id="O3" value="1.40" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability by Treatment Satisfaction Questionnaire for Medications (TSQM) Overall Score.</title>
        <description>The TSQM measures a person's satisfaction with treatment based on a 7-point scale ranging from &quot;Extremely Dissatisfied&quot; to &quot;Extremely Satisfied&quot; in response to the question, &quot;Taking all things into account, how satisfied or dissatisfied are you with this medication?&quot;.</description>
        <time_frame>Week 6</time_frame>
        <population>Data are missing for one participant randomized to receive Placebo treatment due to technical error in not collecting the instrument.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg/Day</title>
            <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
          </group>
          <group group_id="O3">
            <title>10 mg/Day</title>
            <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability by Treatment Satisfaction Questionnaire for Medications (TSQM) Overall Score.</title>
          <description>The TSQM measures a person's satisfaction with treatment based on a 7-point scale ranging from &quot;Extremely Dissatisfied&quot; to &quot;Extremely Satisfied&quot; in response to the question, &quot;Taking all things into account, how satisfied or dissatisfied are you with this medication?&quot;.</description>
          <population>Data are missing for one participant randomized to receive Placebo treatment due to technical error in not collecting the instrument.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Extremely Dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extremely Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AEs)</title>
        <description>AEs will be evaluated and tracked throughout subject participation (up to 8 weeks)</description>
        <time_frame>Up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg/Day</title>
            <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
          </group>
          <group group_id="O3">
            <title>10 mg/Day</title>
            <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs)</title>
          <description>AEs will be evaluated and tracked throughout subject participation (up to 8 weeks)</description>
          <units>Number of adverse events per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.9"/>
                    <measurement group_id="O2" value="2.8" spread="3.6"/>
                    <measurement group_id="O3" value="5.8" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Desaturation Time (DT)</title>
        <description>Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment)</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg/Day</title>
            <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
          </group>
          <group group_id="O3">
            <title>10 mg/Day</title>
            <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Desaturation Time (DT)</title>
          <description>Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="3.46"/>
                    <measurement group_id="O2" value="-0.19" spread="2.78"/>
                    <measurement group_id="O3" value="-0.17" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
Placebo (for Dronabinol)</description>
        </group>
        <group group_id="E2">
          <title>2.5 mg/Day</title>
          <description>Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
Dronabinol</description>
        </group>
        <group group_id="E3">
          <title>10 mg/Day</title>
          <description>Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
Dronabinol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cycling injury</sub_title>
                <description>Struck by vehicle while riding a bicycle</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea or vomiting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleepy</sub_title>
                <description>Increased sleepiness, tiredness or drowsiness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness or lightheadedness</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Euphoria</sub_title>
                <description>Euphoria or feeling &quot;high&quot;</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David W. Carley, PhD</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>312-996-3827</phone>
      <email>dwcarley@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

